GlassScriptPhysician profile
David G Lancaster
NPI 1114136686
$2,109.30
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $365 · 2021: $514 · 2022: $288 · 2023: $546 · 2024: $17.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.63 | 2020-2023 | |
| Ucb, INC. | $181.17 | 2019-2023 | Briviact |
| Emd Serono, INC. | $134.48 | 2020-2023 | Mavenclad |
| Genzyme Corporation | $128.31 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $102.35 | 2019-2023 | Austedo, Austedo Xr |
| Allergan, INC. | $86.78 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $79.24 | 2019-2022 | |
| Grifols USA, LLC | $74.46 | 2023 | Gamunex-C |
| Mallinckrodt Hospital Products INC. | $72.86 | 2020-2021 | |
| Bausch Health US, LLC | $71.84 | 2019 | |
| Amneal Pharmaceuticals LLC | $62.52 | 2021-2023 | Rytary |
| Catalyst Pharmaceuticals, INC. | $56.70 | 2023-2024 | Fycompa |
| Biohaven Pharmaceutical Holding Company LTD. | $55.19 | 2022 | |
| Lilly USA, LLC | $44.07 | 2019-2021 | |
| Lundbeck LLC | $44.07 | 2020-2023 | Vyepti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lancaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.